Schultes Birgit C 4
4 · Intellia Therapeutics, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Schultes Birgit C
EVP, Chief Scientific Officer
Transactions
- Award
Common Stock
[F1]2026-03-01+39,200→ 137,733 total - Award
Stock Option (right to buy)
[F2]2026-03-01+56,000→ 56,000 totalExercise: $13.78Exp: 2036-02-29→ Common Stock (56,000 underlying)
Footnotes (2)
- [F1]Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- [F2]This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.
Signature
James Basta, attorney-in-fact|2026-03-03